Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Yes, losartan can affect kidney function and raise potassium, though serious problems are uncommon and depend on several factors described below. Because losartan blocks angiotensin II, it lowers pressure inside the kidney's filters, which can cause a small, often expected rise in creatinine, but a larger drop in kidney function may occur with dehydration, low blood pressure, NSAID use, diuretics, or narrowing of the kidney arteries. It also reduces aldosterone, so potassium can climb into a dangerous range, especially with chronic kidney disease, diabetes, potassium supplements, salt substitutes, spironolactone, or ACE inhibitors, and warning signs like muscle weakness, numbness, palpitations, or a slow or irregular heartbeat need urgent attention. Routine blood tests for creatinine and potassium after starting or increasing the dose, plus reduced urine output or swelling as red flags, help catch trouble early, and the details below explain when a rise is harmless versus when the drug should be paused. Since these risks hinge on your other medications, hydration, and baseline kidney health, a free, instant, online symptom check can help you sort out whether your symptoms point to high potassium, declining kidney function, or something unrelated, and clarify how soon you should contact a clinician.
Last reviewed for medical accuracy: 09/14/2026
Losartan is an angiotensin II receptor blocker (ARB) commonly prescribed to manage high blood pressure, protect the kidneys in diabetes, and treat heart failure. Like all medications, losartan carries potential side effects. Two concerns often raised are kidney function changes and elevated potassium levels (hyperkalemia). Understanding why these issues can occur, who is most at risk, and how to monitor for them helps you take losartan safely and confidently.
Losartan blocks the action of angiotensin II, a hormone that:
By inhibiting angiotensin II, losartan:
Within the kidneys, angiotensin II constricts the efferent arteriole (the small vessel carrying blood away from the glomerulus). Blocking this effect can:
A mild, early rise in serum creatinine (up to 30%) is expected and generally not harmful. In most people, the kidneys adapt and function stabilizes.
In certain situations, the initial drop in GFR becomes more significant, potentially leading to kidney injury. Risk factors include:
Most people won’t notice symptoms of a mild creatinine rise. However, if kidney function worsens significantly, you may experience:
Routine blood tests—usually within 1–2 weeks of starting losartan or after a dose increase—help detect kidney changes before symptoms appear.
Potassium balance is regulated by aldosterone. Losartan lowers aldosterone production, which can reduce the kidneys’ ability to excrete potassium, leading to hyperkalemia.
Mild elevations may be symptomless. More severe hyperkalemia can cause:
Because serious hyperkalemia can lead to life-threatening heart rhythms, periodic lab checks are essential.
To safely use losartan, follow these practical steps:
Baseline Tests
Early Follow-Up
Ongoing Monitoring
Lifestyle and Diet
Medication Review
If you experience any signs of kidney trouble or hyperkalemia, don’t wait:
For most people, losartan effectively lowers blood pressure, protects the heart, and preserves kidney function in diabetes. Side effects serious enough to stop therapy are uncommon when monitoring is consistent. Open communication with your healthcare team ensures:
Losartan can cause temporary changes in kidney function and raise potassium levels, especially in the presence of other risk factors. Regular lab tests, lifestyle adjustments, and awareness of warning symptoms allow you to reap its benefits while minimizing risks.
If you have any concerns about kidney health, potassium balance, or other side effects, please speak to a doctor. They can tailor monitoring and treatment to your needs and ensure your safety on losartan.
(References)
* Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161. PMID: 11565518.
* Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. PMID: 16029066.
* Hashimoto T, Shibata K, Honda K, Nobe K. Acetic acid treatment causes renal inflammation and chronic kidney disease in mice. J Pharmacol Sci. 2021 Jul;146(3):160-168. doi: 10.1016/j.jphs.2021.04.002. Epub 2021 Apr 16. PMID: 34030798.
* Gao H, Du WY, Lin J, Han SL, Zhang YJ, Sun XF. Losartan Protects Podocytes against High Glucose-induced Injury by Inhibiting B7-1 Expression. Curr Med Sci. 2021 Jun;41(3):505-512. doi: 10.1007/s11596-021-2367-5. Epub 2021 Jun 15. PMID: 34129205.
* Salahuddin, Azam MN, Raja KM, Arshad AR, Khan FR, Mir AW, Tahir T, Butt B, Wahaj, Khan A. The Comparison Of Efficacy Between Losartan And Diltiazem As Antiproteinuric Agent In Non-Diabetic Renal Diseases. J Ayub Med Coll Abbottabad. 2021 Jul-Sep;33(3):492-495. PMID: 34487664.
* Zou J, Zhou X, Ma Y, Yu R. Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. Biomed Pharmacother. 2022 May;149:112931. doi: 10.1016/j.biopha.2022.112931. Epub 2022 Apr 7. PMID: 36068784.
* Ferreira JP, Konstam M, Rossignol P, Kiernan MS, Zannad F. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL. J Card Fail. 2023 Jan;29(1):45-52. doi: 10.1016/j.cardfail.2022.09.008. Epub 2022 Oct 14. PMID: 36244652.
* Nagasawa H, Ueda S, Suzuki H, Jenkinson C, Fukao Y, Nakayama M, Otsuka T, Okuma T, Clapper W, Liu K, Nguyen M, Komers R, Suzuki Y. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nephrol Dial Transplant. 2024 Aug 30;39(9):1494-1503. doi: 10.1093/ndt/gfae021. PMID: 38271614; PMCID: PMC11361813.
* Gyarmati G, Shroff UN, Izuhara A, Deepak S, Komers R, Bedard PW, Peti-Peterdi J. Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS. JCI Insight. 2024 Sep 3;9(19). doi: 10.1172/jci.insight.177775. Epub 2024 Sep 3. PMID: 39226116; PMCID: PMC11466195.
* Zhu Z, Luan G, Wu S, Song Y, Shen S, Wu K, Qian S, Jia W, Yin J, Ren T, Ye J, Wei L. Single-cell atlas reveals multi-faced responses of losartan on tubular mitochondria in diabetic kidney disease. J Transl Med. 2025 Jan 21;23(1):90. doi: 10.1186/s12967-025-06074-5. Epub 2025 Jan 21. PMID: 39838394; PMCID: PMC11748887.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.